June 20, 2017 10:03 AM EDTUpdated 11:12 AM
News Briefing

In wake of a tri­al dis­as­ter, Seat­tle Ge­net­ics files sBLA; Egalet takes a dive on a CRL

Emma Yasinski

→ One day af­ter scrap­ping a Phase III study, Seat­tle Ge­net­ics filed an sBLA for Ad­cetris to treat pa­tients with cu­ta­neous T-cell lym­phoma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

Sanofi touts $20B in­vest­ment in US over five years

A service from the Financial Times